203 related articles for article (PubMed ID: 12942567)
1. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma.
Wollina U; Dummer R; Brockmeyer NH; Konrad H; Busch JO; Kaatz M; Knopf B; Koch HJ; Hauschild A
Cancer; 2003 Sep; 98(5):993-1001. PubMed ID: 12942567
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma.
Akpek G; Koh HK; Bogen S; O'Hara C; Foss FM
Cancer; 1999 Oct; 86(7):1368-76. PubMed ID: 10506727
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies.
Pulini S; Rupoli S; Goteri G; Pimpinelli N; Alterini R; Bettacchi A; Mulattieri S; Picardi P; Tassetti A; Scortechini AR; Fioritoni G; Leoni P
Eur J Haematol; 2009 Mar; 82(3):184-93. PubMed ID: 19215609
[TBL] [Abstract][Full Text] [Related]
4. Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome.
Quereux G; Marques S; Nguyen JM; Bedane C; D'incan M; Dereure O; Puzenat E; Claudy A; Martin L; Joly P; Delaunay M; Beylot-Barry M; Vabres P; Celerier P; Sasolas B; Grange F; Khammari A; Dreno B
Arch Dermatol; 2008 Jun; 144(6):727-33. PubMed ID: 18559761
[TBL] [Abstract][Full Text] [Related]
5. Pegylated doxorubicin for primary cutaneous T-cell lymphoma: a report on ten patients with follow-up.
Wollina U; Graefe T; Kaatz M
J Cancer Res Clin Oncol; 2001 Feb; 127(2):128-34. PubMed ID: 11216914
[TBL] [Abstract][Full Text] [Related]
6. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma.
Duvic M; Apisarnthanarax N; Cohen DS; Smith TL; Ha CS; Kurzrock R
J Am Acad Dermatol; 2003 Jul; 49(1):35-49. PubMed ID: 12833006
[TBL] [Abstract][Full Text] [Related]
7. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy.
Querfeld C; Rosen ST; Kuzel TM; Kirby KA; Roenigk HH; Prinz BM; Guitart J
Arch Dermatol; 2005 Mar; 141(3):305-11. PubMed ID: 15781671
[TBL] [Abstract][Full Text] [Related]
10. Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma: a retrospective study.
Di Lorenzo G; Di Trolio R; Montesarchio V; Palmieri G; Nappa P; Delfino M; De Placido S; Dezube BJ
Cancer; 2008 Mar; 112(5):1147-52. PubMed ID: 18098221
[TBL] [Abstract][Full Text] [Related]
11. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy with carboplatin, paclitaxel and pegylated liposomal doxorubicin for advanced or recurrent carcinosarcoma of the uterus: clinical experience of a single institution.
Pectasides D; Pectasides E; Papaxoinis G; Xiros N; Sykiotis C; Papachristodoulou A; Tountas N; Panayiotides J; Economopoulos T
Gynecol Oncol; 2008 Sep; 110(3):299-303. PubMed ID: 18602677
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
[TBL] [Abstract][Full Text] [Related]
14. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma.
Whittaker SJ; Demierre MF; Kim EJ; Rook AH; Lerner A; Duvic M; Scarisbrick J; Reddy S; Robak T; Becker JC; Samtsov A; McCulloch W; Kim YH
J Clin Oncol; 2010 Oct; 28(29):4485-91. PubMed ID: 20697094
[TBL] [Abstract][Full Text] [Related]
15. Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome.
Safra T; Groshen S; Jeffers S; Tsao-Wei DD; Zhou L; Muderspach L; Roman L; Morrow CP; Burnett A; Muggia FM
Cancer; 2001 Jan; 91(1):90-100. PubMed ID: 11148564
[TBL] [Abstract][Full Text] [Related]
16. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma.
Querfeld C; Rosen ST; Guitart J; Rademaker A; Fung BB; Posten W; Kuzel TM
J Am Acad Dermatol; 2004 Jul; 51(1):25-32. PubMed ID: 15243520
[TBL] [Abstract][Full Text] [Related]
17. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
Olsen EA; Kim YH; Kuzel TM; Pacheco TR; Foss FM; Parker S; Frankel SR; Chen C; Ricker JL; Arduino JM; Duvic M
J Clin Oncol; 2007 Jul; 25(21):3109-15. PubMed ID: 17577020
[TBL] [Abstract][Full Text] [Related]
18. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
[TBL] [Abstract][Full Text] [Related]
19. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
[TBL] [Abstract][Full Text] [Related]
20. Acitretin for the treatment of cutaneous T-cell lymphoma.
Cheeley J; Sahn RE; DeLong LK; Parker SR
J Am Acad Dermatol; 2013 Feb; 68(2):247-54. PubMed ID: 22917895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
